• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The invention relates to amides of polyene macrolide antibiotics and their derivatives characterized by the general formula I, <IMAGE> where R is the polyene macrolide, R1 is an alkyl or isoalkyl chain of from one to eighteen carbons, unsubstituted or substituted with a primary or secondary amine; where R2 is an hydrogen or R1 or R1 and R2 are joined through the nitrogen to form a heterocyclic ring. The method of preparation of these substances according to our invention depends upon the reaction of the polyene macrolide or its derivative in which the carboxylic group is activated; in the environment of an organic solvent or mixture of solvents and in the presence of a substance neutralizing the acid; with a compound containing an amino group; leaving upon completion of the reaction; and precipitation of the product from the reaction mixture, by addition of ethyl ether or a mixture of ethyl ether with hydrocarbons; isolation and purification of the product by means of known methods.
    公开号:SU1017165A3
    申请号:SU802901347
    申请日:1980-04-02
    公开日:1983-05-07
    发明作者:Станислав Фальковски Леонард；Богуслав Яжэбски Анджэй；Янина Стэфаньска Барбара；Трока Эльжбиэта；Боровски Эдвард
    申请人:Политехника Гданьска (Инопредприятие)；
    IPC主号:
    专利说明:

    The invention relates to a method for producing new amide derivatives of antibiotics of the group of polyene macropids or their derivatives of general formula 1.
    0
    / R- l-sh-b
    where R is the residue of the polyene macrolide with the carboxyl group of amphotericin B, pimaricin, aureophacin, polyfungin candicidin, levorin or the residue of its derivative in which the aliphatic amino group is replaced by CgY-dimethylaminomethine or a glycosyl residue;
    RH is an unsubstituted C, - C / g alkyl or C alkyl substituted by another al, kil, phenyl, hydroxy group, phosphoyl group, amino group, dimethyl amino group, urea group and carbomethoxy group, possessing valuable pharmacological properties.
    A known method of condensation of carboxylic acid with amines in the presence of dicyclohexylcarbodiimide tlD.
    The purpose of the invention is to obtain new amides of antibiotics from the group of polyene macrolides and their derivatives with pharmacological activity.
    The goal is achieved by a method based on the well-known tl method, and concludes that in the antibiotic of this group or in its derivative, the carboxyl group is activated using phenyl diester azide of o-phosphoric acid or N-hydroxybenzotriazole in the presence of dicyclohexylcarbodiimide in the medium of an organic and in the presence of t1riethylamine or N-methylmorpholine, after which the product is treated with an aliphatic amine with an alkyl chain length of C - or an aliphatic amine with a length of alkyl chain of C, replacing nym other lower alkyl, phenyl, carboxyl or phosphonium group, amino group, dimethylamino group, or a urea group karbometoksilnoy reaction mixture was allowed to stand to complete the reaction, after which the final product is precipitated by addition of ethyl ether to hexane and, if desired vschel from the reaction mixture by known methods.
    Preferably, M, H-dimethylacetamide, dimethyl sulfoxide, N, M-dimethylforma is used as an organic solvent in the process. mamide or aliphatic alcohol C or mixtures thereof.
    Example 1. 462 mg of Amphotericin B with E 1420 at 382 nm are suspended in 10 ml of VI, N-dimethylacetamide, 0.67 ml of n-hexylamine, 1.02 ml of O-phosphoric acid phenyl diester and 0.68 ml are successively added. triethylamine is left for 4 hours with stirring at room temperature. Then a mixture of ethyl and petroleum ethers fc with a ratio of 1: 1 is introduced into the mixture obtained as a result of the reaction. The precipitate obtained is dissolved in β-butanol and washed twice with water.
    After azeotropic drying, crude amphotericin B n-hexylamide is precipitated from n-butanol with ethyl ether, washed with this solvent and dried in vacuo. Crude amphotericin B n-hexylamide is purified by silica gel column chromatography on water saturated with chloroform: methanol: water (50: 10X1). 265 mg of amphotericin b-hexylamide are obtained with E, cd 1670 at 382 nm, which represents 53% theoretical output. ,
    Ps and Me 2. 66.5 mg of pimaricin with Y / 980 at 304 nm are dissolved in 2 ml of dimethyl sulfoxide, 0.09 ml of morpholine 0.21 ml of phenyl diester b-phosphoric acid azide are successively added and 0, 14 ml of triethylamine, then set in a thermostat at a temperature of 4 hours. Further procedure as in example 1.
    29 mg of Pimaricin morpholinamide were obtained with EICM 800 at 304 nm, which is 40% of the theoretical yield of lCgjj 3, lAlr / Mn.
    EXAMPLE 3 66.5 mg of pimaricin with E 980 at 304 nm are dissolved in 2 ml, N-dimethylformamide, 0.11 ml of benzylamine, 0.21 ml of o-phosphoric acid phenyl azide are added successively. and 0.14 ml of triethylamine, then left at room temperature for 4 hours. Further procedure as in Example 1.
    35 mg of pimaricin benzylamide are obtained with 840 at 304 nm, which is 4J7%. theoretical output, 8 / 4g / mp.
    Example 4. 300 mg of pimaricin with E 980 at 304 nm are dissolved in ml of Kl, N-dimethylacetamide, 0.15 ml of n-butylamine, 0.40 ml of o-phosphoric acid phenyl diester and 0.30 m of triethylamine are sequentially added. for 15 hours at room temperature. Then a mixture of ethyl and petroleum ethers with a ratio of 2: 1 is introduced into the mixture obtained as a result of the reaction.
    The resulting precipitate is dissolved in i-butanol and washed twice with water. After azeotropic purification, the crude product in the form of c-butylamide piiarig is precipitated from α-β-butanol with ethyl ether, washed with this solvent and dried in vacuo.
    250 mg of M-butylamide, pimaricin were obtained at 700 at 304 nm, which is 77% of the theoretical yield of LSd, 1.5 I g / ml.
    Example 5. j., 500 mg of N-glucoelyl polyfungin with Els 480 at 304 nm is dissolved in 2 ml of N, N-dimethylacetamide, 0.11 ml of n-butylamine, 0.60 ml of o-phosphoric acid phosphide azide are successively added and 0.40 ml of triethylamine, after which it is left at a t5 w temperature. A further procedure as in example 1.
    305 mg of N-butylamide, N-glucose of Ilpolyfungin is obtained at 400 at 304 nm, which is 20 to 50% of the theoretical yield. ICU 0.85 / g / ml.
    Example 6, 200 mg aureophaci-. with EiJ23-600 at 382 nm are suspended in 4.0 MP of N, N-dimethylacetamide, 25 are sequentially added with 0.32 ml of N-butylamine, 0.52 ml of phenyl diester azide of o-phosphoric acid and 0.38 of triethylamine, after during rolling it is left at room temperature for 4 hours. Further procedure as in example 1.
    120 g of aureofacin i-butylamide are obtained with a CD of 730 at 382 nm, which is 56% of the theoretical yield of 1C, 0.003 / g / ml.
     PI, Ji mep 7. 150 mg of polyfungin with 700 at 304 nm are dissolved in 5 ml of M, N-dimethylformamide, 0.15 ml of this is successively added. nolamine, 0.15 ml of phenyl dihedral o-phosphoric acid and 0.085 JT of triethylamine, and then left for 12 hours at room temperature. A further procedure as in example 4.
    130 mg of polyfungin 2-hydroxyethyl lamid were obtained with 500 at 304 nm, which is 79% of the theoretical yield, ICjp / L g / ml.
    Example 8: 450 mg of polyfungin with 600 at 304 nm were dissolved in 10 MP M, N-dimethylacetamide, 0.75 ml of 34NiN-dimethylamine-propylamine, 1 ml of azide was added. o-phosphoric acid diester and 0.7 MP of Triethylamine, then left to 3.4 at a setting temperature. Then a mixture of ethyl and petroleum ether in a ratio of 1: 2 is introduced into the mixture obtained as a result of the reaction. The resulting precipitate is dissolved in n-butanol and twice boiled over with water. After aeoeotropic drying, the crude product in the form of 3 - (. M, N-dimethyl) polypungin propylamide precipitates 5
    is given from n-butanol with ethyl ether, washed with solvent and dried in vacuo.
    The crude derivative is purified by column chromatography on a Cefschex layer saturated with water using chloroform: methanol: water (20: 1: 10: 1). 250 mg of 3- {N, Ndimethylamino) propylamide of polyfungin are obtained with, at 304 nm, which is 51% of the theoretical yield. iCgx) 0.13 g / ml.
    Example 9. 450 mg of polyfungin with 600 at 304 nm are dissolved in 10 ml of a mixture of XI, N-dimethylacetamide and dimethyl sulfoxide in a 1: 1 ratio, 80 mg of 3- (1-isopropylamino) propyl 1Mina, 1 MP of phenyl diester phosphoric acid and 0.7 ml of triethylamine, then left under stirring for 4 hours at room temperature. After this time, the formed precipitate of triethylgiline hydrochloride is separated in a centrifuge. The next procedure is as in example 4.
    350 mg of 3- (M-isopropylamino-propylamide polyfungin with
    440 at 304 nm, which is -71% of the theoretical yield. 1C 0, Example 10. 450 mg of polyfugin with 600 at 304 nm are dissolved in 10 ml of methanol by N, N-dimethylacetamide in a ratio of 1: 4, 1 ml of phenyl diester o-phosphoric acid 0.7 ml is added triethylamine, then left for 6 hours at a temperature. A further procedure as in prize 4 is obtained. 370 mg of 1- (N, N-dimethylamino) lysopropylamide polyfungin with E 1% 480 at # 304 HMV, which is 77% of the theoretical yield. IC, 12; Yag / ml.
    P and p 11. 923 mg of amphotericin B with 1420 at 382 nm are suspended in 30 ml of M, H-dimethylacetamide, 1.57 ml of n-decylamine, 2.04 ml of o-phosphoric acid azide and 1, are added successively. 38 ml of triaulamine, then left under stirring at room temperature for 5 hours. A mixture of ethyl ether and petroleum ether was introduced into the reaction mixture in a ratio of 1: 1. The precipitate obtained is purified by a countercurrent separation method for chloroform:: methanol: water in a ratio of 2: 2: 1. 280 mg of amphotericin B n-decylamide are obtained. 1160 at 382 nm which is 26% of the theoretical yield. Yag / ml
    Example 12. 923 mg of amphoteric HjiHHa B with 1420 at 382 nm are suspended in a mixture of 20 ml of M, N-days of tilformamide and 10 ml of methanol, 1 ml of isobutylamine, 204 ml of o-phosphoric acid phosphoric acid and 1 , 38 ml of triethylamine, then left under stirring at room temperature for 4 hours. Further procedure as in Example 11. 300 mg of amphotericin b isobutylamide are obtained with EICM 1420 at 382 nm, which is 31% of the theoretical yield. 1C50 0.059. g / ml Example 13. 923 mg of amphotericin B with 1420 at 382 nm are suspended in 25 ml of S, N-dimethylacetate, 1.21 ml of cyclohexylamine, ml of o-phosphoric phenyl diester and 1.38 ml of triethylamine are subsequently added, after which left under stirring at a temperature of 20 ° C for 5 hours. A further procedure as in Example 11 is obtained. 270 mg of amphetericin iiklogeksilamid, 1350 at 382 nm are obtained, which is 22% of the theoretical yield. 0, 085 D1 g / ml. Approx. 14. 923 mg of amphotericin B with E 1420 at 382 nm are suspended in 20 ml of VJtK-dimethylformamide, 0.86 ml of isopropyl mine, 2.04 ml of o-phosphoric acid phosphoric acid and 1.38 ml of triethylamine are added and then left under stirring at room temperature for 5 hours. A further procedure as in Example 11. Amphotericin b isopropylamide is 370 at E 1300 at 382 nm, which is 38% of the theoretical yield. 0.097. / 61g / ml. Example 15. 923 mg of amphotericin B with 1420 at 382 nm are suspended in 25 g / w of N, N-dimethylformamide, 2690 mg of n-octadecylamine, 2.04 ml of phenyl diester o-phosphoric acid HI1.38 ml of triethylamine are sequentially added, then left under stirring at room temperature for 5 hours. Then an excess of n-octadecylamide is separated in a centrifuge. A further procedure as Example 11. Obtain 220 mg of amphotericization 780 o-octadecylamide 780 at 383 nm, which is 19% of the theoretical yield of 1C50 of 0.21 g / ml in B with E. Example 16. Amphotericin B, 923 mg, and 382 nm are suspended in 20 ml of K1, 0 -7 7 ml of 3-aminopropanol-1, 2.04 ml of o-phosphoric acid phenyl ester and 1.5 ml are added to the solution. L1-methylmorphine, then left under stirring at 25 ° C for 4 hours. This procedure is as in Example 1. 340 mg of amphotericin 3-hydroxypropylamide are obtained from 1400 at 382 nm, which is 35% of the theoretical yield. 1C 0.041 g / ml. . Example 17: 923 mg of amphotericin B, 1420 at 382 nm are suspended in 35 ml of N, M-dimethylacetamide, 2 g of ethyl diester hydrochloride, 3-aminopropanophosphoric acid, 2.04 ml of phenyl diester azide, o -phosphoric acid and 3.45 mp of triethylamine, then left under stirring at room temperature for 4 hours, then the precipitate of triethylamine hydrochloride is separated in a centrifuge. The following procedure is as in Example 11. 340 mg of amphotericin B 3-phosphonimethyl-propylamide are obtained at 1350 at 382 nm, which represents 32% of the theoretical yield. 1C5-0 0.19 g / ml. Example 18. 923 mg of amphotericin B, with 1430 at 382 nm, are suspended in 25 ml of a mixture of VJ, N-dimethylformamide and dimethyl sulfoxide in the ratio of 4: 1, 1859 mg of dodecylamine, ml of o-phosphoric acid phenyl diester and 1.38 ml of triethylamine are successively added and then left at a temperature of 20 ° C with stirring for 5 hours. The Dalbnix procedure is as in Example 11. 230 mg of amphotericin B n-dodecylamide are obtained from 1040 at 382 nm, which is 21% of the theoretical yield. lC (jo 4.9 g / ml. Example 19. 923 mg of Amphoteridin B is suspended in 14 ml of S, M-dimethylacetamide at 1420 at 382 nm, 1.26 ml of 1,3-diaminopropane and 2.04 ml of azide are successively added o-phosphoric acid phenyl ester and 1.38 ml of triethylamine, and then left at room temperature for 4 hours. A further procedure as in Example 11. Obtain 190 mg of 3-aminopropylamide Amphoteric B from 980 at 382 nm, which is. O % theoretical yield of 1C „0. Example 2p: 923 mg of amphotericin B, 1420 at 382 nm, are suspended in 25 ml of N /, N-dimethylacetamide, 1535 mg of chlorine are added successively Methyl ester (α-aminobutyric acid), 2.04 ml of phenyl diester o-phosphoric acid azide and 3, 45 ml of triethylamine, then left under stirring at room temperature for 5 hours, then the hydrochloride precipitate is separated in a centrifuge triethylamine. Further procedure as in Example 11. 210 mg of 3-carboxyethoxypropylamide-amphotericin B 0 E 1100 are obtained at 382. HM, which is 21% of the theoretical yield. 1C60 0.0.071 g / ml. Example 21. 921 mg of amphotericin B at 382 nm are suspended in 20 ml of K /, N-dimethylformamide, 1.65 ml of n-octylminine, 2.04 ml of phenyl diester o-phosphoric acid and 1.38 ml of triethylamine are added, then left under stirring for 4 hours at room temperature. Further procedures are as in Example 11. 240 mg of amphotericin B-1140 m-octylamide at 1182 are obtained at 382 nm, which is 23% of the theoretical yield. 0.24 /) G / mp. Example 22. 923 mg of amphotericin BCE YCM 1420 at 382 nm are suspended in 20 ml of N, N-dimethylacetaceta, 1 ml of piperidine, 2.04 ml of phenylyl ohigraphic disphiric o-phosphoric azide are added, and 1.38 ml of triethylamine, after This was compounded by stirring at room temperature for 4 hours. A further procedure as in Example 11. 2EO mg of amphotericin B piperidylamide B with E iso is obtained at 382 nm, which is 25% of the theoretical yield. 1C, 0.14 g / ml. Example 23, 923 mg of amphotericin B with 1420 at 382 nm are suspended in 20 ml of M, I-dimethylacetamide, 740 mg of glycine 2.04 amide of phenyl diester o-phosphoric acid and 1.38 ml of triethylamine are added. then left under stirring at room temperature for 5 hours. A further procedure as in Example 11. 300 mg of N-amphotericinil B-glycine p E, 900 are obtained at 1382 nm, which is 31% of the theoretical yield. IC 0.06 / g / MP. And p. And mer. 24. 66.5 mg pimarites with E ™ 980 at 304 nm are dissolved in 2 ml of MjN-dimethylacetamide, 0.09 ml of aniline 0.21 phenyl diester o-phosphoric acid and 0 , 14 ml of triethyla on, and then left at room temperature for 4 hours. Further procedure as in Example 1m. 30 mg of Pimaricin anilide are obtained with an E 800 at 304 nm, which is 31% of the theoretical yield. , Example 25. 200 mg of candidic acid with E // 800 at 378 nm are suspended in. 4 gll of N, N-dimethylformamide, 0.3 mp of n-butylamine, 0.6 ml of phenyl diester o-phosphoric acid azide and 0.3 ml of triethylamine are sequentially added, and then left under stirring at room temperature for 6 hours A further procedure as in Example 4. 160 mg of candicidin n-butylamide are obtained with E, D 600 at 378 nm, which is 75% of the theoretical yield. lCi; o 0.01 g / ml. Example 26. 200 mg of levorin CB 800 at 378 nm are suspended in 5 C, M-dimethylacetamide, 0.3 ml of I-butylamine, 0.6 ml of phenyl diester o-phosphoric acid azide and 0.3 ml of triethylamine are subsequently added. then left under stirring for 5 hours at room temperature. A further procedure as in Example 4. 150 mg of levorine n-butylamide are obtained with E = 1.550 at 378 nm, which is 70% of the theoretical yield. 1C 0.15 g / ml. Example 27. 6500 mg poly-. the fungins with E, at 304 nm, are dissolved in 120 ml of K1, N-dimethylacetamide, 8.75 ml of 3- (S, M-dimethylamino) propylsminmine, 14 ml of phenyl azide of phosphoric acid and 9.8 ml are added triethylamine, then left at room temperature for 3 hours. A further procedure as in Example 11. 1770 mg of 3- (m 1 dimethylamino) propylamide polyfungin are obtained with E / j {580 at 304 nm. It is suspended in 160 ml of water, 467 ml of L-aspartic acid is added, and then left for 10 minutes at room temperature. Then 250 ml of n-butanol is added to the solution, and water is removed by azo tropic. From n-butanol precipitated with help. ethyl ether, washed with this solvent and dried in vacuo. 2100 mg of L-aspargate 3- (MDcymethylamino) propylamide polyfungin are obtained with at 304 nm, which is 25% of the theoretical yield. 1CL 0. Example 28. 150 mg of aureofacin with 600 at 382 nm are suspended in 2 ml of W, N-dimethylacetamide and -0.4 ml of acetylacetone is added with stirring. The resultant was left at room temperature for 16 hours with continuous stirring. The crude product, in the form of Y Chpenten-2-on-3-ylo-2) -aypeophacin, is precipitated with ethyl ether, separated in a centrifuge and washed with ethyl ether and hexane. 130 mg of N-f-penten-2-on-3-ylo-2) -aureophacin are obtained with 800 at 382 nm, which is dissolved in 2 ml of N, N-dimethylacetamide and 0.15 mp of ethanolamine, 0.15 ml are added successively. MP azide phenyl diester o-phosphoric acid and 0.085 mp triethylamine. The resulting residue is left at room temperature for 16 hours, and the product obtained is isolated from the mixture resulting from the reaction, separated with ethyl ether in a centrifuge, dissolved in n-butanol, and washed twice with water. After azeotropic removal of water, the resulting 2-hydroxyethylamide - ((penten-2-one-2-ylo-2) aureophacin is precipitated with ethyl ether, separated in a centrifuge, washed again with ethyl ether and hexane, and then dried. Obtain 110 mg of amide 700 at 382 nm, which is 70% of the theoretical yield. 0, g / ml.
    Example 29. 150 mg of polyfungin with 600 at 304 nm are suspended in 2 ml of M, M-dimethylacetamide, 0.2 ml of ethyl acetate is added. The resultant was left under stirring at room temperature for 16 hours. Then 2 ml of butanol was added, and the excess ethyl acetate was evaporated under reduced pressure, after which 0.1 ml of ethanolamine and 0.15 ml of phosphoric acid phosphide azide were added successively. and 0.085 ml of triethylamine. The resultant was left at room temperature for 16 hours and the product was precipitated with ethyl ether, separated in a centrifuge and again washed with ethyl ether, and then dried. Get 110 MOP 2-hydroxyethylamide. h - (1-carboethoxy-propen-1.-ylo-2) -polyfungin with 600 at 304 nm, which is 70% of the theoretical yield. iCyo 0.5 JUr / ml.
    P and measures 30. 70 MrNjN-dimethylaminomethinepimaricin from 1100 at 304 nm is dissolved in 2 ml of M, N -dimethylaceticum and 0.1 ml of N-butylamine, 0.21 ml of o-phosphoric acid phosphide azide and 0 , 14 ml of triethylamine. The reaction mixture is left for 4 hours at room temperature, and then the product obtained is precipitated with ethyl ether, separated in a centrifuge and heated with ethyl ether and hexane, and then dried. 50 mg of i-butylamide M - (m, M-dimethylaminomethine pimaricin are obtained from 1000 at 304 nm, which is 75% of the theoretical yield. ICgo 4.0 1 g / ml.
    EXAMPLE 31. 20 mg of amphotericin B with EII 1400 at 382 nm dissolve 5 5 ml of N, N-dimethylacetamide and add 200 mg of N, N -dicyclohexy silcarbodiimide and 150 mg of 1-hydroxybenzene triethanol. The resultant is left for 30 minutes at room temperature with continuous: 1 vnim stirring. The resulting product is precipitated with ethyl ether, separated in a centrifuge, washed with ethyl ether and dried. Then it is dissolved in 4 ml of N, N-dimethyladetamide, 0.1 ml of U-UtilcC silumin is added and the mixture is left at room temperature for 24 hours. The Ctipofl product is precipitated with ethyl ether, washed again with ethyl ether, dried and partitioned chromatography on silica gel; chloroform: methanol S water: 50: 10: 0.8. 120 mg of amphotericin B with E 1640 at 382 nm, which is 60% of the theoretical yield, are obtained. iCyo 0.08 g / ml.
    Examples 32-37. In the same way as in the examples, the following amides, presented in the table.
    n-ButylPolyfungin amid640
    n-Octyl Same am600 Note
    1-10
    0.18
    24-G28
    0.75 1С5,, 1g / ml: Candididine n-butylamide 0.01 / and levorine butylamide 0.015., 11 10171 Antifungal activity was determined by serial dilutions in OTUCxueHiqiSacctiat-ndes cerev-isiae in a liquid nutrient medium Saburo. As a measure of activity taken con-. 50% slow growth of the microorganism, determined spectrophemetrically 660 nm, after, 24 hours of incubation at a temperature S cXlCjo), as a measure of toxicity, k, Shn / aripta and the concentration of the studied derivatives, causing in standard conditions 50% hemolysis of human erythrocytes (BN). 512 The exclusion of these two quantities, i.e. the ratio of EH to IC is taken as a measure of the selective toxicity in Niivo of the obtained derivatives (polyene $ g of macrolides l.Sl). The advantage of the obtained derivatives is the preservation of their high antifungal activity and more advantageous properties in the field of selective toxicity w vi-tvo compared with the original antibiotics. In addition, salts of amides of polyene macrolides are soluble in water.
    权利要求:
    Claims (2)
    [1]
    1. METHOD FOR PRODUCING AN AMIDES OF ANTIBIOTICS FROM THE GROUP OF POLYENE MACROLIDES OR THEIR DERIVATIVES OF THE GENERAL FORMULA
    B-C-SH-Bi where R is the residue of a polyene * macrolide with a carboxyl group - amphotericin B, pimaricin, aureofacin, polyfungin, candicidin, levorin or a residue of its derivative in which the aliphatic amino group is substituted with Ν, Ν-dimethylaminomethine or glycosyl
    - unsubstituted С ^ ~ С 1е- alkyl, or ; Ci - C.4. - alkyl / substituted with another alkyl, phenyl, oxy group, phosphonium group, amino group, dimethylamino group, urea and carbomethoxy group, characterized in that, in the antibiotic of this group or its derivative, the carboxyl group is activated with the phenyl diester azide of O-phosphoric acid acid or N-hydroxybenzotriazole in the presence of dicyclohexylcarbodiimide in an organic solvent and in the presence of triethylamine or N-methylmorpholine, after which the product is treated with an aliphatic amine with an alkyl length of noy circuit 4 "¢¢ 9 or an aliphatic amine with an alkyl chain length of C ^ -. Sd, other lower substituted alkyl, phenyl, carboxyl or phosphonium group, amino group, dimethylamino group, or a urea group karbometok strong, the reaction mixture was allowed to stand to complete the reaction, after which the final product is precipitated with ethyl ether with the addition of hexane, if desired, and isolated from the reaction mixture.
    [2]
    2. The method according to claim 1, characterized in that N, N-dimethylacetamide, dimethyl sulfoxide, M, M-dimethylformamide or aliphatic alcohol-C, or mixtures thereof, are used as an organic solvent.
    ^ SU ,, 1017165 A
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1017165A3|1983-05-07|Process for preparing amides of antibiotics from group of polyene marcolides or their derivatives
    EP0861236B1|2002-02-13|Cyclic and heterocyclic n-substituted alpha-iminohydroxamic and carboxylic acids
    Bush et al.1951|The production of 3-nitropropionic acid by a strain of Aspergillus flavus
    SU1537135A3|1990-01-15|Method of producing quinazoline amides
    FI87766B|1992-11-13|FORM OF THERAPEUTIC ACTIVATION OF THERAPEUTIC ACTIVE N- | BENZENE DERIVATIVES
    US3174964A|1965-03-23|Derivatives of 6-aminopenicillanic acid
    DE19542189A1|1997-05-15|New cyclic alpha-imino:hydroxamic acid derivatives
    DE1695897A1|1972-02-03|N-acyl-sydnonimine derivatives
    EP0030009B1|1983-05-11|New derivatives of the 9-cis-6,6&#39;-diapo-psi,psi-carotenedioic acid, preparation thereof and pharmaceutical compositions containing same
    US3705175A|1972-12-05|Indazole-3-carboxylic amides
    SU698532A3|1979-11-15|Method of preparing pyrido | pyrimidine derivatives
    US4691018A|1987-09-01|Pyridine derivatives and their use as anti-allergic agents
    SU1609449A3|1990-11-23|Method of producing indenthiazol
    SU645557A3|1979-01-30|Method of obtaining bezamide derivatives or salts thereof
    Endo et al.1974|Screening of compounds structurally and functionally related to N-methyl-N'-nitro-N-nitrosoguanidine, a gastric carcinogen
    Wang1974|Synthesis and properties of N-acetimidoyl derivatives of glycine and sarcosine
    Wolf et al.1951|Amides and amino acid derivatives of biotin
    EP0137132A2|1985-04-17|Process for the manufacture of 7,16-dioxa-2-aza-10-0-cladinosyl-12-0-desosaminyl-4,5-dihydroxy-6-ethyl-3,5,9,11,13,15-hexamethyl-bicyclo|-hexadeca-1|-ene-8-one and novel intermediate used in this process
    EP0514791B1|1998-03-25|Crystalline acid addition salts of diastereomerically pure 1-|-ethylester of 3-cephem-4-carboxylic acid
    SK64098A3|1998-10-07|Production of a salt of clavulanic acid
    US3227709A|1966-01-04|Derivatives of cephalosporin c and process
    FR2461705A1|1981-02-06|NOVEL 1- | -2,3-DIOXOPIPERAZINE DERIVATIVES AND THEIR CARCINOSTATIC ACID ADDITION SALTS AND METHODS FOR PREPARING SAME
    SU569287A3|1977-08-15|Method of preparation of benzhydryloxyalkylamine derivatives or salts thereof
    US2752359A|1956-06-26|Antimicrobial agents
    JP2862912B2|1999-03-03|5 &#39;-| benzoxazinolifamycin derivative
    同族专利:
    公开号 | 公开日
    BE882710A|1980-07-31|
    NL8002086A|1980-10-13|
    FR2453645A1|1980-11-07|
    GB2049658B|1983-08-03|
    DE3013631A1|1980-10-23|
    DE3013631C2|1986-08-28|
    SE450639B|1987-07-13|
    PL122086B1|1982-06-30|
    JPS55157598A|1980-12-08|
    GB2049658A|1980-12-31|
    FR2453645B1|1982-11-19|
    SE8002627L|1980-10-10|
    NO800995L|1980-10-10|
    JPS5728715B2|1982-06-18|
    US4783527A|1988-11-08|
    PL214802A1|1980-12-01|
    FI801099A|1980-10-10|
    SU1152954A1|1985-04-30|
    FI70226C|1986-09-15|
    FI70226B|1986-02-28|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US4035568A|1971-06-07|1977-07-12|Rutgers Research And Educational Foundation|Derivatives of polyene macrolide antibiotics|
    US4041232A|1976-02-23|1977-08-09|E. R. Squibb & Sons, Inc.|Amphotericin B methyl ester salts|
    PL100966B1|1976-04-22|1978-11-30|METHOD OF OBTAINING N-GLYCOSYL DERIVATIVES OF POLYENUM MACROLIDES AND THEIR SALT, ESPECIALLY N-METHYL GLUCAMINE SALT|FR2598434B1|1986-05-12|1988-09-16|Pf Medicament|NEW IMMUNOMODULATORS OBTAINED BY HEMISYNTHESIS FROM A BACTERIAL POLYSACCHARIDE ISOLATED FROM AN UNCAPSULATED MUTANT STRAIN OF KLEBSIELLA PNEUMONIAE|
    FR2614306B1|1987-04-22|1989-07-28|Pf Medicament|NOVEL D.25 DERIVATIVE, PROCESS FOR THE PREPARATION THEREOF, USE AS AN IMMUNOSTIMULATING AGENT AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME.|
    DE3836599A1|1988-10-27|1990-05-03|Wolff Walsrode Ag|NEW POLYSACCHARIDES, METHOD FOR THEIR PRODUCTION AND THEIR USE|
    IT1237772B|1989-11-16|1993-06-17|Tiberio Bruzzese|POLYENIC MACROLID DERIVATIVES.|
    IT1243404B|1990-12-03|1994-06-10|Prodotti Antibiotici Spa|PARTICULATE DERIVATIVES|
    WO2001051061A1|2000-01-14|2001-07-19|Intrabiotics Pharmaceuticals, Inc.|Derivatives of polyene macrolides and preparation and use thereof|
    US6664241B2|2000-05-31|2003-12-16|Micrologix Biotech Inc.|Water-soluble amide derivatives of polyene macrolides and preparation and uses thereof|
    ES2323253B1|2005-03-23|2010-04-23|Consejo Sup. De Invest. Cientificas|NEW POLIENES AMIDED, PROCEDURE FOR OBTAINING AND APPLICATIONS.|
    WO2006100330A2|2005-03-23|2006-09-28|Consejo Superior De Investigaciones Cientificas|Polyene antibiotics, compositions containing said antibiotics, method and micro-organisms used to obtain same and applications thereof|
    ES2323397B1|2005-08-03|2010-04-23|Consejo Sup. De Invest. Cientificas|MACROLIDOS METHODED POLYENES, PROCEDURE FOR OBTAINING AND APPLICATIONS.|
    WO2009015541A1|2007-07-30|2009-02-05|Shanghai Institute Of Pharmaceutical Industry|Polyene diester antibiotics|
    MX365184B|2010-12-21|2019-05-21|Centro De Investig Y De Estudios Avanzados Del I P N|New amphotericin analogous compounds and pharmaceutical compositions containing them.|
    EP3156410A4|2014-06-12|2018-01-03|Shionogi & Co., Ltd.|Polyene macrolide derivative|
    CN113574061A|2019-01-31|2021-10-29|西格马-奥尔德里奇有限责任公司|Antifungal agents with improved water solubility|
    RU2751333C1|2020-12-16|2021-07-13|Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт по изысканию новых антибиотиков имени Г.Ф. Гаузе"|Method for obtaining antifungal semisynthetic polyene antibiotic|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    PL1979214802A|PL122086B1|1979-04-09|1979-04-09|Process for preparing amides of antibiotics from the group of polyene macrolides and their derivativesvykh makrolidov i ikh proizvodnykh|
    [返回顶部]